Eli Lilly LLY Other immunology — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Eli Lilly in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Eli Lilly's other immunology — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Eli Lilly's other immunology — revenue?
- Eli Lilly (LLY) reported other immunology — revenue of $470M in Q1 2026.
- How has Eli Lilly's other immunology — revenue changed year-over-year?
- Eli Lilly's other immunology — revenue increased by 44.2% year-over-year, from $326M to $470M.
- What is the long-term trend for Eli Lilly's other immunology — revenue?
- Over 4 years (2021 to 2025), Eli Lilly's other immunology — revenue has grown at a 167.5% compound annual growth rate (CAGR), from $32.9M to $1.68B.
- What does other immunology — revenue mean?
- This metric represents the total net sales generated from the company's secondary or emerging immunology product portfolio, excluding primary blockbuster therapies. It captures the revenue contribution from niche or early-stage immunological treatments that address specific autoimmune or inflammatory conditions. Monitoring this segment provides insight into the company's ability to diversify its immunology pipeline and capture market share in specialized therapeutic areas.